Progenra
Biotechnology company focused on discovery and preclinical development of small-molecule therapeutics that modulate the ubiquitin–proteasome system. Core programs include discovery of targeted protein degraders (PROTACs and molecular glues), deubiquitinase inhibitors (e.g., USP7 inhibitors) and small-molecule activators of mitochondrial quality-control pathways (Parkin/PINK1). Activities include in vitro target validation, medicinal chemistry, in vivo efficacy testing, patenting and industry partnerships.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Targeted protein degradation discovery technology
Discovery technology and workflows to identify small molecules that induce targeted degradation of proteins via the ubiquitin–proteasome system.
Small-molecule USP7 inhibitor series (preclinical)
Series of small-molecule inhibitors targeting the deubiquitinating enzyme USP7 developed and patented for anticancer and immuno-oncology indications.
Small-molecule Parkin/PINK1 activator programs (preclinical)
Programs to identify and optimize small molecules that activate Parkin or PINK1 signaling for treatment of Parkinson's disease and mitochondrial dysfunction.
Targeted protein degradation discovery technology
Discovery technology and workflows to identify small molecules that induce targeted degradation of proteins via the ubiquitin–proteasome system.
Small-molecule USP7 inhibitor series (preclinical)
Series of small-molecule inhibitors targeting the deubiquitinating enzyme USP7 developed and patented for anticancer and immuno-oncology indications.
Small-molecule Parkin/PINK1 activator programs (preclinical)
Programs to identify and optimize small molecules that activate Parkin or PINK1 signaling for treatment of Parkinson's disease and mitochondrial dysfunction.
Services
Collaborative programs and partnered research to discover and optimize small molecules targeting ubiquitin-related pathways.
Collaborative programs and partnered research to discover and optimize small molecules targeting ubiquitin-related pathways.
Expertise Areas
- Targeted protein degradation
- Ubiquitin pathway drug discovery
- Neurodegenerative disease therapeutics (Parkinson's disease, mitochondrial pathways)
- Immuno-oncology small-molecule development
Key Technologies
- Targeted protein degradation (PROTACs, molecular glue approaches)
- Small-molecule deubiquitinase inhibition
- Small-molecule kinase activation (PINK1/Parkin pathway modulation)
- Biochemical and cell-based screening assays
News & Updates
Regular presentations and session organization at conferences focused on targeted protein degradation, immuno-oncology and drug discovery (examples include Discovery on Target, PROTAC/TPD conferences, AACR, ACS).
Press release describing progress on small-molecule activators of PINK1 kinase and programs targeting the PINK1/Parkin signaling pathway.
Press release describing a discovery relevant to precision therapy for mitochondrial dysfunction disorders.
Award supporting development of small-molecule Parkin activators for Parkinson's disease (funding for discovery and preclinical development).
Composition-of-matter patent covering a first series of USP7 inhibitors (US 8,680,139).
Official notice of allowance for a patent application covering methods of treating cancer through USP7 inhibition and immune system modulation.
Regular presentations and session organization at conferences focused on targeted protein degradation, immuno-oncology and drug discovery (examples include Discovery on Target, PROTAC/TPD conferences, AACR, ACS).
Press release describing progress on small-molecule activators of PINK1 kinase and programs targeting the PINK1/Parkin signaling pathway.
Press release describing a discovery relevant to precision therapy for mitochondrial dysfunction disorders.
Award supporting development of small-molecule Parkin activators for Parkinson's disease (funding for discovery and preclinical development).
Composition-of-matter patent covering a first series of USP7 inhibitors (US 8,680,139).
Official notice of allowance for a patent application covering methods of treating cancer through USP7 inhibition and immune system modulation.